{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:35Z","timestamp":1793394095653,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101387","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:47:45Z","timestamp":1773301665000},"page":"101387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies"],"prefix":"10.1016","volume":"76","author":[{"given":"David J.","family":"Kuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigbj\u00f8rn","family":"Berentsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep S.","family":"Dudani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelufar","family":"Mozaffarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101387_bb0005","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101387_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101387_bb0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101387_bb0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B Cell\u2013Directed Therapy in Autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2026.101387_bb0025","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","article-title":"Sequential immunotherapy: towards cures for autoimmunity","volume":"23","author":"Ram\u00edrez-Valle","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2026.101387_bb0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2026.101387_bb0035","first-page":"102923","article-title":"Results from a phase 2 study on mezagitamab for chronic\/persistent primary immune thrombocytopenia","volume":"9","author":"Kuter","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101387_bb0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0039-1700512","article-title":"Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment","volume":"46","author":"Al-Samkari","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2026.101387_bb0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/JBM.S259101","article-title":"Management of Adult Patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice","volume":"12","author":"Song","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2026.101387_bb0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia","volume":"170","author":"Hill","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0055","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/17474086.2024.2372333","article-title":"The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms","volume":"17","author":"Berentsen","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.19495","article-title":"Cognitive impairment among patients with chronic immune thrombocytopenia","volume":"205","author":"Kuter","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0070","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study","volume":"145","author":"Kuter","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0075","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0080","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjh.20257","article-title":"Patient survey in immune thrombocytopenia (ITP): identifying unmet needs related to treatment and disease control in patients living in the United States","volume":"207","author":"Cooper","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/jcm10010164","article-title":"Infectious complications in autoimmune hemolytic Anemia","volume":"10","author":"Giannotta","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2026.101387_bb0090","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/17474086.2021.1976635","article-title":"Risk of infection in adult patients with primary immune thrombocytopenia (ITP): a systematic review","volume":"14","author":"Sandvad","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0095","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0100","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate Mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100647","article-title":"Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations","volume":"41","author":"Zaja","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101387_bb0115","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.17334","article-title":"Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study","volume":"193","author":"Lucchini","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.blre.2026.101387_bb0125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.18773","article-title":"B cells and antibodies in refractory immune thrombocytopenia","volume":"203","author":"Roeser","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0135","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2026.101387_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0145","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0155","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2024-201418","article-title":"A phase 2 study of Ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy: interim results from VAYHIT3","volume":"144","author":"Kuter","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0160","article-title":"Ianalumab plus Eltrombopag in immune thrombocytopenia","volume":"0","author":"Cuker","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0165","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101387_bb0170","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2026.101387_bb0175","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2026.101387_bb0180","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0185","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19\u2212CD38hiCD138+ subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2026.101387_bb0190","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/bloodadvances.2017004481","article-title":"Long-lived plasma cells in human bone marrow can be either CD19+ or \u2013CD19","volume":"1","author":"Brynjolfsson","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101387_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101726","article-title":"Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture","volume":"75","author":"Mujtahedi","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.blre.2026.101387_bb0200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101387_bb0205","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1002\/ajh.25932","article-title":"Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy","volume":"95","author":"Tomkins","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0210","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","article-title":"Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease","volume":"8","author":"Jalink","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101387_bb0215","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0220","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMc2501527","article-title":"Daratumumab in relapsed or refractory pediatric immune thrombocytopenia","volume":"392","author":"Sun","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2025017279","article-title":"Safety and efficacy of Daratumumab in immune thrombocytopenia","volume":"10","author":"Tsykunova","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101387_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084314","article-title":"Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial","volume":"391","author":"Chen","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2026.101387_bb0235","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101387_bb0240","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMc2502297","article-title":"BCMA-targeted T-cell engager for autoimmune hemolytic Anemia after CD19 CAR T-cell therapy","volume":"392","author":"Zhang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0245","article-title":"Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity","volume":"134","author":"Bodansky","year":"2026","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101387_bb0250","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.blre.2026.101387_bb0255","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","article-title":"Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the autoimmune diseases working party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"57","author":"Alexander","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101387_bb0260","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/08916930802198436","article-title":"Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias","volume":"41","author":"Passweg","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.blre.2026.101387_bb0265","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101387_bb0270","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2026","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101387_bb0275","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.blre.2026.101387_bb0280","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jprot.2017.01.012","article-title":"Identification of novel autoantigens via mass spectroscopy-based antibody-mediated identification of autoantigens (MS-AMIDA) using immune thrombocytopenic purpura (ITP) as a model disease","volume":"157","author":"Kamhieh-Milz","year":"2017","journal-title":"J Proteomics"},{"key":"10.1016\/j.blre.2026.101387_bb0285","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101387_bb0290","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2026.101387_bb0295","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \u201cless-is-more\u201d in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.blre.2026.101387_bb0300","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001436","article-title":"Obinutuzumab effectively depletes key B-cell subsets in blood and tissue in end-stage renal disease patients","volume":"9","author":"Looney","year":"2023","journal-title":"Transplant Direct"},{"key":"10.1016\/j.blre.2026.101387_bb0305","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti\u2013BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101387_bb0310","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0315","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101387_bb0320","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010064","article-title":"Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis","volume":"12","author":"Liang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2026.101387_bb0330","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0335","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0340","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0345","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0350","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0355","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101387_bb0360","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0365","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic Purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2026.101387_bb0370","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2026.101387_bb0375","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2018-12-885228","article-title":"Low-dose rituximab in autoimmune hemolytic anemia: 10 years after","volume":"133","author":"Fattizzo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0380","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.16672","article-title":"Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia \u2013 follow-up of the RITP study","volume":"191","author":"Tj\u00f8nnfjord","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0385","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0390","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.20951","article-title":"The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab","volume":"82","author":"Kuwana","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101387_bb0395","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101387_bb0400","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2026.101387_bb0405","article-title":"High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura","volume":"132","author":"Canales-Herrerias","year":"2026","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101387_bb0410","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101387_bb0415","series-title":"ASH Annu. Meet. 2025 Orlando FL","article-title":"Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy","author":"Choi","year":"2025"},{"key":"10.1016\/j.blre.2026.101387_bb0420","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjh.17655","article-title":"Daratumumab in rituximab-refractory autoimmune haemolytic anaemia","volume":"194","author":"Rieger","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101387_bb0425","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30472","article-title":"Successful sequential therapy with rituximab and daratumumab for refractory posttransplant immune thrombocytopenic purpura","volume":"70","author":"Shino","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101387_bb0430","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor\u2013related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2026.101387_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002742","article-title":"Daratumumab for the treatment of refractory ANCA-associated vasculitis","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.blre.2026.101387_bb0440","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajt.2023.12.010","article-title":"Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Angeletti","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2026.101387_bb0445","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ajt.2024.06.010","article-title":"Rescue with obinutuzumab and daratumumab as combined B cell\/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence","volume":"24","author":"Randone","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2026.101387_bb0450","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ekir.2024.04.006","article-title":"Combined rituximab and daratumumab treatment in difficult-to-treat nephrotic syndrome cases","volume":"9","author":"Angeletti","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.blre.2026.101387_bb0455","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with Daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"CHEST"},{"key":"10.1016\/j.blre.2026.101387_bb0460","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae163.016","article-title":"OA16 clinical and biochemical improvement following daratumumab therapy for anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease: a case report","volume":"63","author":"Koh","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.blre.2026.101387_bb0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","article-title":"Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells","volume":"405","author":"Trautmann-Grill","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2026.101387_bb0470","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2403743","article-title":"Anti\u2013CD19 CAR T cells in refractory immune thrombocytopenia of SLE","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0475","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJMoa2509820","article-title":"CD19 CAR T-cell therapy for autoimmune hemolytic anemia","volume":"394","author":"Li","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0480","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood-2024-202980","article-title":"CD19 CAR T-cell therapy in refractory autoimmune hemolytic anemia","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0485","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101387_bb0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-137545","article-title":"Autoimmune hemolytic anemia: a disease of the elderly and the very elderly with increased mortality and increased rates of hospitalization for thrombosis and infection","volume":"136","author":"Maquet","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101387_bb0495","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","article-title":"Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis","volume":"23","author":"Weycker","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.blre.2026.101387_bb0500","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3324\/haematol.2016.146373","article-title":"Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome","volume":"101","author":"Grimaldi-Bensouda","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101387_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2026.101387_bb0510","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2026.101387_bb0515","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101387_bb0520","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-025-01321-w","article-title":"Humoral vaccine responses following chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"15","author":"Einarsdottir","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101387_bb0525","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ard.2025.05.458","article-title":"POS0061\u00a0BCMA-CD19 dual-targeting CAR-T cell for the treatment of refractory thrombocytopenia associated with autoimmune diseases","volume":"84","author":"Yang","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101387_bb0530","series-title":"A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma","author":"Rade","year":"2025"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:08:24Z","timestamp":1788221304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":106,"alternative-id":["S0268960X26000263"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101387","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101387"}}